This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Auna S.A. (AUNA) Q1 Earnings Top Estimates
by Zacks Equity Research
Auna S.A. (AUNA) delivered earnings and revenue surprises of 90% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
RenovoRx (RNXT) delivered earnings and revenue surprises of 0% and 1.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Auna S.A. (AUNA) Reports Next Week: What You Should Expect
by Zacks Equity Research
Auna S.A. (AUNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
by Zacks Equity Research
Here is how Auna S.A. (AUNA) and Coya Therapeutics, Inc. (COYA) have performed compared to their sector so far this year.
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
by Zacks Equity Research
COO's fiscal first-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
Canadian Natural to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
CNQ is expected to report lower revenues than the year-ago period. The company is anticipated to see a higher bottom line due to declining costs.
Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Auna S.A. (AUNA) and BioMarin Pharmaceutical (BMRN) have performed compared to their sector so far this year.
Sea Limited to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SE's fourth-quarter performance is likely to have benefited from strong Shopee and SeaMoney growth. Competition and FX volatility are expected to have hurt profitability.
Agilent Q1 Earnings Beat Estimates, Stock Falls on Cautious FY25 View
by Zacks Equity Research
A's first-quarter fiscal 2025 results benefit from strong LC & services, but margin contraction raises investor concerns.
Wall Street Analysts Predict a 39.33% Upside in Auna S.A. (AUNA): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Auna S.A. (AUNA) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
by Zacks Equity Research
Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.